HOME >> MEDICINE >> NEWS
Leading cancer doctor calls for new guidelines to control early reporting from clinical trials

Hamburg, Germany: A leading breast cancer doctor is urging researchers to consider changing the guidelines that govern whether clinical trials should be stopped prematurely, as she believes that current practice could be damaging research efforts.

Dr Martine Piccart, head of the chemotherapy unit at the Institut Jules Bordet, Brussels, Belgium, is putting proposals for new guidelines to the Breast International Group (BIG) and, if BIG agrees, the issue would be discussed with the North American Breast Intergroup.

She said that breast cancer research had not been well served by trials of adjuvant therapies aimed at preventing cancer returning, which had reported their results early, because this could mean that some questions about long-term efficacy and side effects or untoward effects remained unanswered, and the future of other trials was put at risk.

"Researchers need to achieve a better balance between informing doctors and women quickly about a more effective treatment for breast cancer and the equally important need to collect solid data on the safety of the therapy," she told a discussion group at the 4th European Breast Cancer.

Three recent trials* of aromatase inhibitors (AIs) as adjuvant treatments for breast cancer had all reported results early because they showed significant advantages for AIs over tamoxifen, but Dr Piccart said that an average follow-up time of only 30 months did not enable doctors to weigh up the long-term risks and benefits of the different treatments. If the trials had continued for longer it was possible that the risks of the different treatments would have become clearer (for instance, tamoxifen carries a risk of endometrial cancer and blood clots, whereas AIs carry a risk of osteoporosis and bone fractures), therefore allowing doctors to conduct a useful risk-benefit analysis an integral part of making appropriate decisions about the best treatment for a patient.

She said early reporting
'"/>

Contact: Emma Mason
wordmason@aol.com
49-403-569-3625
Federation of European Cancer Societies
18-Mar-2004


Page: 1 2 3

Related medicine news :

1. Leading researchers in allergic disease to gather for 2005 AAAAI Annual Meeting
2. Leading tobacco manufacturer conceals links to tobacco research facility
3. Leading MRSA experts address emergence of superbug
4. Leading causes of blindness for blacks and whites different
5. Leading AIDS experts criticize US-sponsored HIV vaccine trial in Thailand
6. Leading the way in novel anti-cancer research
7. Leading American, German chemists converge to share research, vision
8. Leading anti-cancer factions strengthen bonds
9. Leading NIH-funded medical schools agree on guidelines that would strenghten conflict of interest policies
10. Biochemical Marker Targets Brain Injury Leading To Movement Problems After Stroke
11. New Model Shows How To Eradicate Worlds Leading Infectious Cause Of Blindness

Post Your Comments:
(Date:5/24/2015)... Metamora, Michigan (PRWEB) May 24, 2015 ... for concerns about hair loss. Although it is unclear ... that there are environmental factors such as metabolism, nutritional ... contribute. Since they offer a comprehensive approach to evaluating ... and post-menopausal woman, they can help patients find a ...
(Date:5/24/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... tests, which will allow them to take pressure measurements ... about bladder function. The doctor usually orders it if ... or overactive bladder (OAB). , Women’s Excellence ... that have problems with unwanted urinary leakage or problems ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 EnviroLeather™ ... launches “InkGard™ Plus” – a classic, rugged leather ... polymer allowing difficult stains, including ink, to be ... different colors suitable for corporate, healthcare, hospitality and ... line with EnviroLeather’s goal of developing products that ...
(Date:5/24/2015)... Viejo, CA (PRWEB) May 24, 2015 ProPin ... use in Final Cut Pro X. Utilize ProPin to pin ... in a given scene. , ProPin allows users to ... completely customizable in FCPX. With on-screen controls, video editors can ... allows users to pin and mark with absolute ease. , Using ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Medicx Media Solutions Expands Executive Team 2
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
(Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
(Date:5/22/2015)... 2015 Today, Rhodes Pharmaceuticals L.P. announced that ... indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) ... The announcement comes just one ... U.S. Food and Drug Administration (FDA). ... methylphenidate capsule with an onset of effect of ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
Cached News: